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mediately resistant to all azoles. The several possible mechanisms of azole
resistance have been reported previously, but the exact resistant mechanism is
not clear. In this study, we identified differentially expressed genes (DEGs) of
fluconazole-resistant C. glabrata and compared the gene expression of fluco-
nazole-resistant strains with that of fluconazole-susceptible strains to identify
gene corresponding to fluconazole resistance.
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Objectives
Candida glabrata has become one of the most common causes of Candida
bloodstream infections worldwide. Some strains of C. glabrata may be inter-
used for further study. The expression of CgCDR1 and CgCDR2 genes was
investigated by slot hybridization against fluconazole-susceptible, -resistant,
and resistant-induced strains. In addition, ERG3 and ERG11 genes were
sequenced to analyze DNA base substitution. DEGs were identified by reverse
transcription-polymerase chain reaction using DEG kit composed of 120 random
primers.
Results
In slot hybridization, CgCDR1 gene was expressed more than CgCDR2 gene in
resistant strains. Though base substitution of ERG11 and ERG3 genes was
observed in several base sequences, just one amino acid change was identified in
resistant strain. In the results of reverse transcription-polymerase chain reac-
tion, 44 genes were upregulated and 34 genes were downregulated. Among
them, adenosine triphosphate-binding cassette transporter-related genes, fatty
acid desaturase, lyase, and hypothetical protein genes were upregulated andicrobial Resistance, Center for Infectious Diseases, Korea National Institute of Health, 194,
Korea.
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Identification of fluconazole resistance-related gene from C. glabrata 37aldehyde dehydrogenase, oxidoreductase, and prohibitin-like protein genes were
downregulated. Other DEGs were also identified.
Conclusion
This study showed that CgCDR1 gene was more closely related to fluconazole
resistance of C. glabrata than CgCDR2 gene. In addition, several other genes
related with fluconazole resistance of C. glabrata were identified.1. Introduction
Since the early 1980s, fungi have emerged as major
causes of human infectious diseases, especially
among immunocompromised patients and those
hospitalized with serious underlying disease.1e3
Candida is the agent most frequently implicated in
invasive fungal infections, and it now ranks as the
fourth most common cause of nosocomial blood-
stream infections, accounting for 8% of all hospital-
acquired bloodstream infections in the United
States.4,5 Among intensive care unit patients, it is
the third most common cause of nosocomial blood-
stream infections.6 A recent trend noted in many
hospitals is an increase in the prevalence of Candida
glabrata as a cause of serious Candida infections.7,8
The rise in the number of C. glabrata systemic
infections deserves a great deal of concern because
of the high mortality rate associated with C. glab-
rata infection. The incidence of invasive candidiasis
has increased worldwide in recent decades.9 Multiple
antifungal agents are available for the treatment of
candidiasis. Azole drugs, one of the four classes of
antifungals, especially fluconazole, were commonly
used in clinical practice. The extensive use of flu-
conazole has led to the increasing occurrence of
resistant isolates. Especially, C. glabrata is yeast
with intrinsically low susceptibility to fluconazole
and is often recovered from clinical samples origi-
nating from AIDS or cancer patients.10 Four main
mechanisms of azole resistance have been
described:11 mutations in ERG11 gene; increases in
the copy number of the azole target; the blockage of
the ergosterol biosynthesis pathway; and the over-
expression of genes coding some adenosine triphos-
phate (ATP)-binding cassette or major facilitator
superfamily efflux pumps, leading to the increasing
efflux of azole drugs. Although several possible
mechanisms of azole resistance have been reported
previously, the exact resistant mechanism is not
clear. And there is little gene information about
fluconazole resistance in C. glabrata. In this study,
we investigated gene expression of fluconazole-
resistant strains compared to susceptible strains to
identify gene corresponding to fluconazole resis-
tance. We used gene fishing primers, including 120
random primers, to discover gene for fluconazole
resistance and identified gene.2. Materials and Methods
2.1. Clinical strains
In this study, a total of 56 C. glabrata strains were
collected from tertiary hospitals. The source of
C. glabrata strains were blood, urine, sputum, and
others. And just one strain was collected per patient. The
collected strains were subcultured onto Sabouraud
dextrose agar and CHROMagar Candida medium
(CHROMagar Co., France) to ensure their viability and
purity. Cultures were routinely inoculated from single
colony and grown at 30C in yeast extract peptone
dextrose (YEPD) (10 g of yeast extract, 20 g of peptone,
and 20 g of dextrose per liter) or on YEPD agar plates
(10 g of yeast extract, 20 g of peptone, 20 g of dextrose,
and 15 g of agar per liter), stored at 4C, and subcultured
weekly, or stored at 80C in YEPD containing 10%
glycerol. Using the source information and genetic
background like restriction fragment length poly-
morphism, pulse-field gel electrophoresis pattern (data
not shown), fluconazole-susceptible strain D-31
(minimal inhibitory concentration [MIC] 1 mg/mL),
susceptible dose-dependent (SDD) strain D-284 (MIC
16 mg/mL), and resistant D-116 (MIC 256 mg/mL)
strain were selected for further study.
2.2. Antifungal susceptibility testing
Antifungal susceptibility testing of Candida strains to
fluconazole was performed in exact accordance with the
reference broth microdilution method described in the
M27-A2 guidelines of the Clinical and Laboratory
Standards Institute (formerly NCCLS).12
2.3. Fluconazole-resistant induction
To investigate the expression signal change of CgCDR1
and CgCDR2 genes against fluconazole susceptibility
step, fluconazole-susceptible D-31 strain was induced to
be fluconazole resistant. C. glabrata D-31 strain was
cultured in YEPD broth including fluconazole 1 mg/mL
at the beginning, and the concentration of fluconazole
was increased continuously up to 64 mg/mL. The MIC
was confirmed with broth microdilution method and E-
test experiment. The slot hybridization results were
compared to results of susceptible, SDD, and resistant
strains.
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The CgCDR1 and CgCDR2 genes were used for slot
hybridization to analyse the patterns of gene expression
of C. glabrata strain. Using polymerase chain reaction
(PCR), CgCDR1, CgCDR2, and 26S ribosomal RNA
products were synthesized, purified, and labelled by
a random prime labelling kit (Amersham, Co., PA,
USA). For hybridization experiment, nitrocellulose
membrane was soaked in distilled water and in 20
saline-sodium citrate solution for 1 hour at room
temperature. Sample RNA was added to the membrane
and washed two to three times with 10 saline-sodium
citrate solution, and the membrane was dried with
a vacuum instrument. The RNA was fixed on the
membrane with ultraviolet and hybridized. Signals were
detected using an enhanced chemiluminescence detec-
tion kit (Amersham, Co., PA, USA). In slot hybridiza-
tion experiment, fluconazole resistant-induced strains
were also tested against CgCDR1 and CgCDR2 gene
expression.2.5. CgERG3 and CgERG11 sequence analysis
Using three selected strains (fluconazole susceptible,
SDD, resistant), ERG3 and ERG11 genes were detected
by specific PCR with the use of ERG3-F, ERG3-R,
ERG11-F, and ERG11-R primers complementary to the
regions of ERG3 and ERG11 genes. The genomic DNA
was used for PCR template. PCR ran in GeneAmp 2700
apparatus (Perkin-Elmer, Co., CA, USA) under the
condition 25 cycles of PCR amplification with Taq DNA
polymerase (Takara Shuzo Co., Shiga, Japan). Anneal-
ing reaction was done at 50C, and extension reaction
was done at 72C. The product was confirmed with
electrophoresis at 1.2% agarose gels. The PCR products
of ERG3 and ERG11 genes were purified by PCR
purification kit (Qiagene GmbH, Hilden, Germany) and
directly sequenced.2.6. Gene identification
Cells from 24-hour cultures grown in YEPD were
inoculated in 200 mL of YEPD at starting concentration
of 2  104 cells/mL. The cultures were grown overnight
at 30C with agitation. Total RNAs were prepared from
the cultures of susceptible, SDD, resistant strains at
optical density of 600 nm of 0.3 value using RNeasy
mini kit (Qiagen GmbH, Hilden, Germany). Total RNAs
extracted from fluconazole-susceptible, -SDD, and
-resistant strains were used for the synthesis of first-
strand complementary DNAs (cDNAs) by reverse tran-
scriptase. Reverse transcription was performed for 1.5
hours at 42C in a final reaction volume of 20 mL con-
taining 3 mg of the purified total RNA, 4 mL of 50
reaction buffer (Promega, Madison, WI, USA), 5 mL ofdeoxynucleotide triphosphates (each 2 mM), 2 mL of 10-
mM deoxythiamine annealing control primer 1(ACP-1)
(50-CTGTGAATGCTGCGACTAC GATIIIIIT-30),
0.5 mL of RNasinO` RNase inhibitor (40 U/mL; Prom-
ega), and 1 mL of Moloney murine leukaemia virus
reverse transcriptase (200 U/mL; Promega). First-strand
cDNAs were diluted by the addition of 80 mL of ultra-
purified water for GeneFishing PCR and stored at
20C until use. Differentially expressed genes were
screened by the ACP-based PCR method using GeneF-
ishing differentially expressed gene kits (Seegene,
Seoul, South Korea). Briefly, second-strand cDNA
synthesis was conducted at 50C during one cycle of
first-stage PCR in a final reaction volume of 20 mL
containing 3e5 mL (about 50 ng) of diluted first-strand
cDNA, 1 mL of dT-ACP2 (10 mM), 1 mL of 10 mM
arbitrary ACP, and 10 mL of 20 Master Mix (Seegene).
The PCR protocol for second-strand synthesis was one
cycle at 94C for 1 minute, followed by 50C for 3
minutes, and 72C for 1 minute. After second-strand
DNA synthesis was completed, the second-stage PCR
amplification protocol was 40 cycles of 94C for 40
seconds, 65C for 40 seconds, and 72C for 40 seconds,
followed by a 5-minute final extension at 72C. The
amplified PCR products were separated in 2% agarose
gel and stained with ethidium bromide. The differen-
tially expressed bands were re-amplified and extracted
from the gel using GENCLEANO` II Kit (Q-BIO gene,
Carlsbad, CA, USA) and directly sequenced with ABI
PRISMO` 3100-Avant Genetic Analyzer (Applied Bio-
systems, Foster City, CA, USA).
3. Results
3.1. Expression of CgCDR1 and CgCDR2 genes
In the results of hybridization experiments, the fluco-
nazole-resistant D-116 strain showed increased expres-
sion of CgCDR1 gene than the susceptible (D-31) and
SDD (D-284) strains. CgCDR2 gene expression also
increased in the fluconazole-resistant strain than in the
susceptible strain, but the signal was weaker than the
CgCDR1 gene signal (Figure 1A). The fluconazole
resistant-induced strain showed increased expression of
CgCDR1 and CgCDR2 compared to susceptible strain.
But CgCDR1 gene responded first to the fluconazole
resistance induction environment (Figure 1B).
3.2. CgERG3 and CgERG11 sequence analysis
Three C. glabrata strains showed the same predicted
product size against ERG3 and ERG11 genes
(Figure 1C). Three point mutations of ERG3 gene were
observed in T435C, T317A, and G423A. In addition,
two amino acid changes were also observed
(Leu106Gln, Glu139Ala) including one in the
Figure 1 The results of RNA slot blot hybridization of fluconazole-susceptible, -SDD, and-resistant Candida glabrata strains.
(A) C. glabrata-susceptible (D-31), -SDD (D-284), -resistant (D-116) strains, and 26s ribosomal RNA (quantity control). (B)
Results of RNA expression from fluconazole resistant-induced isolate (MIC 1, 8: susceptible, MIC 16: SDD, MIC 64: resistant). (C)
Lane 1: 1-kb marker, PCR product of ERG3 (Lane 2e4) and ERG11 (Lane 5e7) genes. Lane 2 and Lane 5: C. glabrata D-31 strain
(susceptible), Lane 3 and Lane 6: C. glabrata D-284 strain (SDD), Lane 4 and Lane 7: C. glabrata D-116 strain (resistant). The
PCR product was sequenced. SDDZ susceptible dose dependent; MICZ minimal inhibitory concentration; PCRZ polymerase
chain reaction.
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tions were shown in ERG11 gene but no amino acid
change (Table 1).
3.3. Gene identification
When 120 random primers were used, the expression of
258 genes increased or decreased (Figure 2). Among
these genes, 78 genes showed more than two times
expression difference between fluconazole-susceptible
and -resistant strains. Finally, 44 genes were of higher
expression and 34 were of lower expression in the flu-
conazole-resistant strain than in the susceptible strain.
Among the 44 genes, 13 were identified as fumarate
hydratase, manganese transporter, transcriptional regu-
lation mediator, adenosine diphosphate/ATP carrier
protein, and other proteins. All of the proteins were
corresponding to Saccharomyces cerevisiae, Saccharo-
myces kluyveri, and C. glabrata protein. The 34 less
expressed genes included aldehyde dehydrogenase,
oxidoreductase, and prohibitin-like protein gene. TheTable 1 Base substitution and amino acid changes of ERG3 an
tible, -susceptible dose-dependent, and -resistant strain
Base substitution
Susceptible (C. glabrata D-31) T435C
S-DD (C. glabrata D-284) T317A
T435C
Resistant (C. glabrata D-116) G423A
T435C
The amino acid change was shown in ERG3 sequence from all C. glabrata st
C. glabrataZ Candida glabrata.ATP-binding cassette transporter was identified in both
patterns (Table 2).
4. Discussion
Candida species is one of the major organisms of fungal
infections. Recently, C. glabrata has emerged as
a common cause of bloodstream and mucosal infections.
The major mechanisms of fluconazole resistance among
C. glabrata described to date have been primarily based
on CgCDR1, CgCDR2, and ergosterol synthesis
pathway enzymes. The CgCDR1 and CgCDR2 gene
upregulation and the point mutation of ERG3 and
ERG11 genes are known to have related with flucona-
zole resistance of C. glabrata. However, there is not
much information on other genes contributing to the
fluconazole resistance of C. glabrata. In this study, we
discovered that 258 genes were expressed differentially
between fluconazole-susceptible and -resistant strains.
Among them, 73 genes showed higher or lower
expression in the resistant strain compared to thed ERG11 genes from Candida glabrata fluconazole-suscep-
s
Erg3 Erg11
Amino acid change Base substitution
Glu139Ala T768C
Leu106Gln T768C
Glu139Ala T834C
A1593G
Glu139Ala C588T
T768C
C918T
rains, but there was no amino acid change in Erg11 gene sequence.
Figure 2 Differently expressed genes were screened by the reverse transcription-PCR method using GeneFishing DEG kits. RNA
was purified from three Candida glabrata strains (1: susceptible, 2: susceptible dose dependent, 3: resistant). The DEGs were cloned
and sequenced. A total of 258 genes showed higher or lower expression in the resistant strain compared to the susceptible strain. The
PCR product with numbers is selected for the sequencing. PCRZ polymerase chain reaction; DEGZ differentially expressed gene.
40 J.I. Yoo et alsusceptible strain. Most of the identified genes were
assigned to S cerevisiae because of insufficient infor-
mation on C. glabrata gene even though the full
sequence of C. glabrata was recently published.13 The
identified gene products were corresponded to amino
acid metabolism, cell wall synthesis, energy productionTable 2 Identification of differently expressed genes from reve
Increased expression
Saccharomyces cerevisiae
Tryptophanyl-tRNA synthetase
Carnitine O-acetyltransferase
Peroxisomal long-chain fatty acid import protein 2
Fumarate hydratase
Manganese transporter
Transcriptional regulation mediator
General transcriptional adaptor or co-activator
Component of actin cortical patches
Negative regulator of ras-cAMP pathway
AAC2 ADP/ATP carrier protein
Involved in cell wall biogenesis and architecture
Gamma-glutamylphosphate reductase
Acetyl-CoA synthetase
Candida glabrata
Carnitine acetyltransferase gene
ATP-binding cassette transporter
Saccharomyces kluyveri
Putative citrate synthase gene
A total of 258 genes showed increased or decreased expression. Among them
tRNAZ transfer RNA; cAMPZ cyclic adenosine monophosphate; AAC2 A
CoAZ coenzyme A; GTPZ guanosine triphosphate.protein, tricarboxylic acid cycle enzyme-related prod-
ucts, oxidoreductase, prohibitin-like protein, and others.
Among the identified genes, specifically ATP-binding
transporters increased or decreased. Because ATP-
binding transporters like CgCDR1 and CgCDR2 genes
showed higher expression in the fluconazole-resistantrse transcription-polymerase chain reaction
Decreased expression
Saccharomyces cerevisiae
DNA-dependent ATPase/DNA helicase B
GTP cyclohydrolase II
Prohibitin antiproliferative protein
Methionine aminopeptidase
Aldehyde dehydrogenase
Oxidoreductase
prohibitin-like protein
Candida glabrata
ATP-binding cassette transporter
, 78 genes were selected for product cloning and sequencing.
DP/ATPZ adenosine diphosphate/adenosine triphosphate carrier 2;
Identification of fluconazole resistance-related gene from C. glabrata 41strain than in the susceptible strain, other ATP-binding
transporters related to fluconazole resistance are of high
interest. The expression of CgCDR1 has higher fluco-
nazole-resistant levels than in the concentration of
CgCDR2 expression.10 In our study, the hybridization
experiment of CgCDR1 and CgCDR2 genes also showed
that the expression of CgCDR1 gene was more increased
than CgCDR2 compared to susceptible strain. And the
expression of fluconazole resistant-induced strain
showed that CgCDR1 gene was first increased to the
fluconazole stress. This result supposes that CgCDR1
gene is the main gene corresponding to fluconazole
resistance. And the point mutation of ERG3 gene was
observed in three DNA bases. And it caused amino acid
changes. The position of base substitution of ERG3 gene
was different from the position previously reported.14e16
Usually, the point mutation of ERG3 or ERG11 gene is
related with fluconazole resistance.17,18 But the results
of this study need more sequence analysis using more
fluconazole-susceptible strains to confirm the results.
Finally, in this study, we identified a few genes whose
expression increased or decreased in fluconazole-resis-
tant strain. But the exact mechanism of how resistance is
mediated has not been answered. Thus, it is necessary to
study the functions of meaningful genes including
transporter-related gene except already known CgCDR1
and CgCDR2 genes.Acknowledgement
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